Trial Profile
A Randomised, Double-blind, Placebo Controlled Study to Evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics Profile of SLx-4090 Over 14 Days Dosing in Subjects With High Triglyceride Values
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs KD 026 (Primary)
- Indications Hypertriglyceridaemia
- Focus Therapeutic Use
- Sponsors Surface Logix
- 29 Jan 2008 Status changed to completed in accordance with media release 9084666.
- 21 Jun 2007 New trial record.